XGN
The “is this thing actually working?” quarter
Exagen came out swinging with a quarter that looked a lot less like wishful thinking and a lot more like a business finding its footing. Revenue rose 16%, average selling prices hit a record, and adjusted EBITDA got close to breakeven — which is corporate-speak for “we’re not burning quite as much cash while we figure this out.”
Why the bulls are getting louder
The real headline isn’t just that the company did better. It’s that management raised full-year revenue guidance to $72 million-$75 million, which tells you this wasn’t a one-off lucky bounce. Add in Pharma Services revenue tripling and backlog growing, and you’ve got two new growth levers that could help the company look a lot less like a one-product story.
Profitability: still a climb, but the ladder is sturdier
Operating margin improved to -8.6%, and Q2 cash generation turned positive. That matters because investors don’t just want growth — they want growth that doesn’t eat the company’s lunch money. Positive cash generation is the kind of detail that makes a turnaround thesis feel less like a motivational poster and more like a spreadsheet.
Big picture
Exagen still has work to do before anyone starts popping champagne, but the path to profitability just got more believable. If the company can keep scaling revenue, widen margins, and avoid a detour back into cash-burn land, this could go from “interesting turnaround” to “actually investable.”